cannabidivarin
Small moleculeexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01918735)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCC)cc1O- Mol. weight
- 286.42 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2387742 ↗
Also known as
- cannabidivarin
- cannabidivarin (cbdv)
- gwp42006
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03848481 | Phase 2 | Sep 30, 2019 | Foundation for Prader-Willi Research, Yeshiva University |
| NCT03849456 | Phase 2 | May 31, 2019 | GW Research, University of Louisville |
| NCT03202303 | Phase 2 | Oct 1, 2017 | Department of Defense, Yeshiva University |
| NCT03537950 | N/A | Aug 22, 2016 | University of London |
| NCT02365610 | Phase 2 | Mar 1, 2016 | GW Research, University of London |
| NCT02369471 | Phase 2 | Mar 1, 2015 | GW Research, University of London |
| NCT01918735 | Phase 1 | Aug 1, 2013 | GW Research, Quotient |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GW Research | For profit | 4 | 4 | 2 | 2013 |
| University of London | Academic/Hospital | 3 | 1 | 2 | 2015 |
| Yeshiva University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Department of Defense | Government | 1 | 0 | 1 | 2017 |
| Foundation for Prader-Willi Research | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Quotient | For profit | 1 | 0 | 1 | 2013 |
| University of Louisville | Academic/Hospital | 1 | 0 | 1 | 2019 |
7 organizations
Page 1 / 1